In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Celgene's Abraxane Stock, Trading Earn-Outs Is The Exception Not The Rule

Executive Summary

Though Abraxane (paclitaxel) is now part of Celgene Corp.'s growing oncology portfolio, you don't need Celgene stock to invest in its newest product, a reformulation of the generic chemotherapy that's approved to treat metastatic breast cancer. As part of Celgene's cash-and-stock $2.9 billion acquisition of Abraxis BioScience Inc. Celgene deferred at least $650 million in potential payments to Abraxis shareholders, plus royalty payments tied to Abraxane sales. Unlike most earn-out-laden deals, however, the contingency value rights, or CVRs, for the earn-outs have been securitized and now trade under the ticker CELGZ. Despite potential advantages - tradeable CVRs let shareholders bet on the success or failure of specific assets, for instance - these investment vehicles are still a rarity in the marketplace.
Advertisement

Related Content

Abraxane White Paper Distribution At ASCO Draws FDA Advertising Letter
How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees
How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Celgene Flexes Its Muscles
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Celgene Flexes Its Muscles
Complex CVR Will Enable Genzyme And Sanofi Shareholders To Share Potential Upside For Lemtrada

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel